Você procurou por: positive anti hmg coa reductase antibody (Inglês - Croata)

hmg-coa reductase
hmg-coa reduktaze mogu

hmg coa reductase inhibitor
inhibitori hmg-coa reduktaze

hmg-coa reductase inhibitors
inhibitori reduktaze hmg co-a

use with hmg-coa reductase inhibitors
primjena s inhibitorima hmg-coa reduktaze

antibody test positive; anti-factor viii antibody test positive
pozitivan test na protutijela; pozitivan test na protutijela na faktor viii

refer to section 4.3 for hmg-coa reductase
pogledati dio 4.3 za inhibitore hmg-coa

concomitant use of hmg-coa reductase inhibitors (‘statins’)
istodobna primjena inhibitora reduktaze hmg-coa (‘statini’)

hydroxy methyl glutaryl coenzyme a (hmg coa) reductase inhibitors
inhibitori hidroksimetilglutaril koenzim a (hmg koa) reduktaze

hmg-coa reductase inhibitors that are sensitive cyp3a substrates may interact with lesinurad.
moguća je interakcija inhibitora hmg-coa reduktaze koji su osjetljivi supstrati cyp3a s lesinuradom.

hmg-coa reductase inhibitors (“statins”): lomitapide increases plasma concentrations of statins.
inhibitori reduktaze hmg-coa („statini“): lomitapid povećava plazmatske koncentracije statina.

posaconazole may substantially increase plasma levels of hmg-coa reductase inhibitors that are metabolised by cyp3a4.
posakonazol može znatno povećati koncentraciju inhibitora hmg-coa reduktaze u plazmi koji se metaboliziraju putem cyp3a4.

hmg-coa reductase inhibitors same recommendations as for indinavir without ritonavir boosting (see table 1).
inhibitori hmg-coa reduktaze vrijede iste preporuke kao i za indinavir koji nije pojačan ritonavirom (vidjeti tablicu 1).

hmg-coa reductase inhibitors metabolised through cyp3a4 (e.g. simvastatin, lovastatin, and atorvastatin)
inhibitori hmg-coa reduktaze koji se metaboliziraju putem cyp3a4 (npr. simvastatin, lovastatin i atorvastatin)

this metabolite has one-tenth to one-fortieth the hmg-coa reductase inhibitor activity of the parent compound.
ovaj metabolit ima jednu desetinu do jednu četrnaestinu inhibitorne aktivnosti osnovnog lijeka za hmg-koa reduktazu.

interactions are also expected with other hmg-coa reductase inhibitors, including atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin.
interakcije se također očekuju s ostalim inhibitorima hmg-coa reduktaze uključujući atorvastatin, fluvastatin, lovastatin, pravastatin i simvastatin.

co-administration with the hmg-coa reductase inhibitors simvastatin, lovastatin and atorvastatin (see section 4.5).
istodobna primjena inhibitora hmg-coa reduktaze simvastatina, lovastatina i atorvastatina (vidjeti dio 4.5).

2 one adult subject had a positive anti-factor viii antibody test result coincident with a single measurement of a neutralising antibody titre of 0.73 bethesda units/ml at week 14.
2 jedan odrasli ispitanik imao je pozitivan rezultat testa određivanja protutijela na faktor viii istovremeno s jednim mjerenjem titra neutralizirajućih protutijela od 0,73 bethesda jedinica/ml u 14. tjednu.

pharmacotherapeutic group: lipid modifying substances, hmg-coa reductase inhibitors in combination with other lipid modifying substances, atc code: c10ba04
farmakoterapijska skupina: lijekovi koji modificiraju lipide, inhibitori hmg-coa reduktaze u kombinaciji s drugim lijekovima koji modificiraju lipide, atk oznaka: c10ba04

if treatment with a hmg-coa reductase inhibitor is indicated, pravastatin or fluvastatin is recommended with careful monitoring (see section 4.5).
ako je indicirano liječenje inhibitorom hmg-koa reduktaze, preporučuju se pravastatin ili fluvastatin uz pomno praćenje (vidjeti dio 4.5).

nine out of 56 patients were persistently positive (anti-vedolizumab antibody-positive at two or more study visits) and 33 patients developed neutralizing anti-vedolizumab antibodies.
devet od 56 bolesnika bili su trajno pozitivni (anti-vedolizumab protutijela pozitivni u dva ili više posjeta tijekom ispitivanja), a 33 bolesnika razvila su neutralizirajuća anti-vedolizumab protutijela.